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We describe a severely immunosuppressed HIV-
1–positive man in whom immune restoration disease asso-
ciated with pulmonary infection caused by Mycobacterium
microti developed after antiretroviral treatment. The diagno-
sis was made by using convenient spoligotyping tech-
niques, but invasive investigations were required to
exclude a tumor.
During the first few months of highly active antiretro-viral treatment, immune restoration may be compli-
cated by clinical events in which either previously
subclinical infections are found or preexisting partially
treated opportunistic infections deteriorate. This condition,
termed immune restoration disease (IRD), is thought to be
caused by the improvement in the host’s immune response
to pathogens. We report what we believe is the first record-
ed case of IRD with confirmed Mycobacterium microti
infection. M. microti is an unusual infection associated
with small rodents. Novel genetic techniques have con-
firmed it as a human pathogen, but its true incidence
remains unclear. 
Case Report
A 33-year-old man was admitted to the hospital in 2002
with a 3-month history of intermittent hemoptysis. He had
previously visited hematology outpatient clinics for many
years for hemophilia A (3%–5% factor VIII) and HIV-1
had been diagnosed in 1996 (a stored sample from 1989
retrospectively tested HIV-1–antibody positive). CD4 cell
counts had been recorded as 434 × 106/L in 1996 and 260
× 106/L in 1998. After this time, he failed to attend any fur-
ther clinic appointments.
In addition to worsening hemoptysis, he had minor
weight loss but no night sweats. He appeared moderately
unhealthy, with oral thrush and mild splenomegaly. A chest
radiograph showed left upper lobe shadowing (Figure 1,
panel A), sputum smears contained numerous acid-fast
bacilli, and sputum was sent for culture, speciation, and
sensitivity testing. Blood tests showed a CD4 cell count of
6 ×106/L and HIV viral load of 272,000 (log 5.4)
copies/mL. His hemoglobin was 12.1 g/dL, leukocyte
count 4.9 × 109/L, and platelets 367 × 109/L. Renal and
liver function test results were normal, apart from a γ-glu-
tamyltransferase level of 200 U/L (normal <35 U/L). An
ultrasound scan of his abdomen showed a diffuse increase
in liver echogenicity and an enlarged (13.6-cm) spleen. He
was naturally immune to hepatitis B, and tests for hepatitis
C antibody and viremia were negative. 
He was given broad-spectrum antimycobacterial thera-
py (rifampin, isoniazid, pyrazinamide, ethambutol, and
azithromycin) as treatment for both M. tuberculosis com-
plex (MTB complex) and opportunistic mycobacteria. He
improved throughout a 2-week hospital stay and highly
active antiretroviral therapy (HAART) was begun. It con-
sisted of zidovudine and lamivudine and an increased dose
of efavirenz (800 mg daily) because of concomitant
rifampicin therapy, together with cotrimoxazole for pro-
phylaxis against Pneumocystis jirovecii.
At a 3-week follow-up appointment, the patient had
continued to improve. No further hemoptysis had occurred,
and he had gained 2 kg body weight. After that, by tele-
phone, he complained of occasional fevers and malaise but
declined to be seen. Nine weeks after his initial visit, he
came to the ward and with symptoms of breathlessness,
nausea, and diarrhea. He had fevers spiking to >38°C, and
newly palpable lymph nodes were evident in the right axil-
la and over the left parotid gland. A chest radiograph
showed increased shadowing (Figure 1, panel B) and a
computed tomographic (CT) scan of the chest showed a
6×3-cm solid mass in the upper left chest with visible air
bronchograms and minor volume loss, reported as “almost
certainly solid neoplasm” (Figure 2). A bronchoscopy,
before which the patient received factor VIII, showed an
area of irregular nodular tissue in the posterior segment of
the left upper lobe. His CD4 count was 26 × 106/L. 
While we awaited histologic examination results, the
patient’s medication was withdrawn, and he improved
within days. The lymph nodes reduced in size, and the
spiking temperature resolved. Eight weeks after admis-
sion, the results of IS6110 polymerase chain reaction
(PCR) testing on the slow-growing, positive mycobacteri-
al culture confirmed the presence of MTB complex. The
bronchial biopsy specimen showed necrotizing granulo-
matous bronchitis; acid-fast bacilli were not visible, and
this specimen did not grow any mycobacteria. 
The Mycobacterium species was not growing well in
the laboratory, but M. microti was identified in the culture
with spoligotyping methods (1,2). On extension of culture,
the isolate was confirmed as M. microti phenotypically and
found to be sensitive in vitro to rifampin, isoniazid, etham-
butol, and clarithromycin but resistant to pyrazinamide. 
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The antimycobacterial drugs were reintroduced without
problems 4 weeks later, as was HAART after an addition-
al 8 weeks. Thirty months after restarting antimycobacter-
ial therapy, the patient remained well with a total weight
gain of 19 kg, complete radiologic resolution of the pul-
monary mass, undetectable HIV viral load (<50
copies/mL), and a progressive rise in his CD4 count to 249
× 106/L.
Conclusions
M. microti is a slow-growing member of the MTB com-
plex. It has most commonly been described in association
with small rodents (2,3). Its role as a pathogen in humans
has been proposed by a handful of case reports involving
both immunocompetent and immunodeficient persons
(4–6). Because of the slow growth of the bacterium, con-
firmatory diagnosis is difficult, and cultures may be
wrongly discarded as negative after a routine 8- to 12-
week culture period. In such cases several commercial
tests can identify the organism to the level of the MTB
complex. The members of the tuberculosis complex are
not reliably distinguished on biochemical grounds.
Restriction fragment length polymorphism, DNA finger-
printing, is a time-consuming, slow, and expensive method
of distinguishing members. Spoligotyping (spacer oligo-
typing) is a PCR-based test that can be quickly performed,
even on the small amounts of DNA in poorly growing cul-
tures. Strains differ in the size of spacer regions that inter-
sperse direct repeat regions. These polymorphisms create
differences in the PCR products produced, a process that
allows strain identification (1,7). Other PCR-based tests
are being developed that may have advantages over spolig-
otyping for identifying some members of the complex (8).
Culture remains the standard and allows drug sensitivity
testing. We suggest that such cultures be extended for up to
6 months if acid-fast bacilli are noted in specimens from a
patient with consistent pulmonary pathologic findings. 
Severe immunosuppression associated with HIV-1 can
allow coinfections to remain subclinical. After HAART is
introduced, IRD can lead to the development of oppor-
tunistic infections with atypical and severe clinical signs
and symptoms. In this case, necrotizing granulomatous
inflammation occurred without isolation of mycobacteria,
which is atypical in an immunodeficient HIV patient.
These clinical manifestations have been described in many
diseases, including MTB and other opportunistic
mycobacterial infections (9), herpesvirus infections, and
hepatitis B and C (10). Similar granulomatous endo-
brochial lesions have been described during immune
restoration with M. avium complex in HIV-infected
patients (11). IRD has been described as occurring in 30%
to 40% of those with very low CD4 counts when they
begin HAART, developing within the first few months of
treatment as the CD4 count rises. IRD is a diagnosis of
exclusion: other processes such as drug fever, resistance,
treatment failure, or other infections must be excluded.
IRD may be a life-threatening condition, and clinical inter-
ventions, such as stopping medications, steroids, or both,
may be indicated. An associated increase in markers of
immune activation occurs, which seems to vary depending
on the pathogen involved (12,13) .
In MTB, the major risk factor for IRD is beginning
HAART within 2 months of antituberculosis treatment.
This fact has led many experts to recommend delaying
HAART for 2 months, a strategy that may also reduce the
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Figure 1. Chest radiographs at initiation of A) highly active anti-
retroviral therapy (HAART) showing left hilar mass; and B) after 9
weeks of HAART and antituberculosis treatment, suggesting
enlargement of the hilar mass consistent with immune restoration
disease. (The radiograph has been flipped horizontally to aid com-
parison.)
incidence of adverse events. However, a recent retrospec-
tive review suggested that delaying HAART would, partic-
ularly in those with CD4 cell counts<100 cells × 106/L,
lead to significant increase in risk for death and new
opportunistic infections (14). IRD should always be con-
sidered along with treatment failure if a patient’s clinical
condition deteriorates after HAART is introduced.
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Figure 2. Computed tomographic scan of thorax at patient’s initial
visit. Results are highly suggestive of tumor.
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